Accretion Nutraveda Link 
Allotment
The Accretion Nutraveda IPO is a book-built issue aggregating ₹24.77 crore. The offering consists entirely of a fresh issue of 0.19 crore equity shares.
The IPO will open for subscription on January 27, 2026, and close on January 30, 2026. The allotment of shares is expected to be finalized on February 2, 2026, with a tentative listing on the BSE SME platform scheduled for February 4, 2026.
The price band for the IPO has been fixed at ₹122 to ₹129 per share. The lot size is 1,000 shares per application. Retail investors are required to apply for a minimum of 2 lots (2,000 shares), translating to an investment of ₹2,58,000 at the upper price band. For HNI investors, the minimum application size is 3 lots (3,000 shares), amounting to ₹3,87,000.
Sobhagya Capital Options Pvt. Ltd. is acting as the Book Running Lead Manager for the issue, while Kfin Technologies Ltd. has been appointed as the registrar.
₹129
0%
Open
₹129
HIgh - Low
₹129
Previous Close
₹129
Total Traded Value
0
52 Weeks High
₹129
52 Weeks Low
₹129
Updates On
Jan 21, 2026
IPO. Open
Jan 28, 2026
IPO. Close
Jan 30, 2026
IPO. Price
₹129.00
IPO Market price
₹93.40 Cr
IPO Details
| IPO Date | 4 Feb |
| IPO Listing Date | 4 Feb |
| IPO Face Value | ₹10.00 per share |
| IPO Price Range | ₹129.00 |
| IPO Issue Size | 19,20,000 shares |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Bookbuilding IPO |
| IPO Listing | BSE SME Platform |
| Share Holding Pre Issue | 53,20,000 shares |
IPO Timeline
| IPO Open Date | 28 Jan |
| IPO Close Date | 30 Jan |
| IPO Allotment (Tentative) | 2 Feb |
| Refunds | 3 Feb |
| Credit to Demat Account | 3 Feb |
| IPO Listing Date | 4 Feb |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | 9,08,000 Shares |
| NII (HNI) Shares Offered | 2,76,000 Shares |
| Retail Shares Offered | 6,40,000 Shares |
IPO Lot Size
Investors can apply for a minimum of 2,000 shares, and bids must be made in multiples of 1,000 shares thereafter.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹2,58,000 |
| Retail (Max) | 2 | 2,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,32,000 |
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and nutraceutical products across a wide range of dosage forms, including tablets, capsules, oral liquids, powders, oils, and external applications such as balms, creams, and gels.
The company operates as a Contract Development and Manufacturing Organization (CDMO), catering to both domestic and international markets, including Sri Lanka, Singapore, and the USA. Its product offerings integrate classical Ayurvedic formulations with modern nutraceutical science, addressing key wellness segments such as liver health, women’s health, bone and joint care, cognitive support, and respiratory wellness.
Business Verticals
Domestic Sales & Merchant Exports (Loan License Basis): Contributed 96.62% of total revenue in FY 2024–25.
Direct Exports: Contributed 38%, reflecting steady growth over recent years.
The company operates a manufacturing facility in Gujarat, spanning approximately 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, segregated processing areas, and robust quality control systems. The facility holds multiple certifications such as GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, Halal, and is licensed by FSSAI.
Competitive Strengths
Experienced promoters and management team
Diverse and scalable product portfolio
Strong commitment to quality and regulatory compliance
Long-standing relationships with clients and suppliers
Well-established business processes and management framework
Company Financials (Consolidated)
| Assets | 10.86 | 4.64 | 4.06 |
| Total Income | 16.06 | 5.2 | 3.07 |
| Profit After Tax | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.65 | 1.21 | 0.59 |
| NET Worth | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 4.86 | 0.72 | -0.1 |
| Total Borrowing | 3.86 | 2.17 | 1.97 |
Key Performance Indicator (KPI)
| ROE | 81.22% |
| ROCE | 36.98% |
| Debt/Equity | 0.72 |
| RoNW | 48.85% |
| PAT Margin | 16.33% |
| EBITDA Margin | 22.79% |
| Price to Book Value | 8.76 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | 8.03 |
| 2 | To meet out the expenses of Working Capital Requirement | 5.5 |
| 3 | To meet out the General Corporate Purposes; | - |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Accretion Nutraveda Ltd. Address
27 Xcelon Industrial Park-1
Vasna-Chacharwadi, TaSanand,
Ahmedabad, Gujarat, 382213
+91- 9904366177
compliance@accretionnutraveda.com
Detail Registrar
IPO Registrar
Kfin Technologies Ltd.
04067162222, 04079611000
apl.ipo@kfintech.com
https://ipostatus.kfintech.com/
India’s nutraceutical and Ayurveda market is expanding rapidly due to preventive healthcare trends, export demand, and lifestyle diseases, positioning Accretion Nutraveda to benefit from sustained industry tailwinds.
CDMO models reduce brand risk, ensure recurring revenue, and benefit from asset-backed manufacturing growth, making companies like Accretion Nutraveda attractive amid rising outsourcing by wellness brands.
Increasing global acceptance of Ayurveda and nutraceutical formulations, especially in the USA and Southeast Asia, supports revenue diversification and improves growth visibility for export-oriented manufacturers.
Automation improves scalability, quality consistency, regulatory compliance, and margin expansion—key factors as nutraceutical manufacturers face rising volumes and stricter global quality standards.
Strong PAT and EBITDA growth indicate operational leverage, which is increasingly favored by investors as SME IPO markets shift focus from revenue growth to sustainable profitability.
Global certifications like WHO-GMP, FSSC, and ISO enable access to regulated export markets, enhancing credibility and competitive positioning amid tightening food and pharma compliance norms.
Compare:
